

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: April 20, 2004 (use as many sheets as necessary)			<b>Complete if Known</b> Application Number: 10/699,563 Filing Date: 11/03/2003 First Named Inventor: Bradford Van Wagenen Group Art Unit: Not yet assigned 1625 Examiner Name: Not yet assigned ZND/AVAS Attorney Docket Number: 085747-0299		
Sheet	1	of	2		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
mgd		3,647,809	A	Harsanyi et al.	3/7/1972	
		4,022,901	A	Narayanan et al.	5/10/1977	
		<del>5,554,630</del>		<del>Teuber et al.</del>	<del>09/1996</del>	
		3,647,809		Reiter et al.	03/1972	
		5,554,630		Teuber et al.	9/10/1996	
		4,003,909		Narayanan et al.	1/18/1977	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
mgd			WO 01 12627 A		NPS Pharmaceuticals Inc.	2/22/2001		
			WO 98 17652 A		Boehringer Ingelheim	4/30/1998		
			WO 99 02497 A		Novartis Erfindungen	1/21/1999		
			WO 97/0396706096		Rhone-Poulenc Rorer Limit	2/1997		
			WO 94/22846		Pfizer Inc.	10/1994		
			WO 94/22846	A1	Pfizer Inc.	10/13/1994		
			WO 97/03967	A1	Rhonepoulenc Rorer Limited GB	02/06/1997		
			WO 99/26927	A2	NPS Pharmaceuticals, Inc.	06/03/1999		
			WO 98/57969		Hoechst Schering	12/1998		
			DE 1 149 011		Farbwerke Hoechst Aktiengesellschaft	5/22/1963		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
X		M. OHKUBO et al., "Studies on Cerebral Protective Agents; VII. Synthesis of Novel 4-Acrylazole Derivatives with Anti-anoxic Activity", Chem. Pharmaceutical Bulletin; June 1995; pp. 947-954; Vol. 43; No. 6; Pharmaceutical Society of Japan.	
X		W. PEI et al., "Convenient Synthesis of 2-Alkyl (Aryl)-4, 5-diphenyloxazoles and 2-Alkyl (Aryl)-4 phenyloxazoles", Synthesis; September 1998, pp. 1298-1304; No. 9, China.	

X Did not receive

Examiner Signature	<i>Linn W Davis</i>	Date Considered	4/8/2005
--------------------	---------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: April 20, 2004  (use as many sheets as necessary)		Application Number	10/699,563
		Filing Date	11/03/2003 APR 20 2004
		First Named Inventor	Bradford Van Wagenen
		Group Art Unit	Not yet assigned 1625
		Examiner Name	Not yet assigned 2A/DK/ST
		Attorney Docket Number	085747-0299

Sheet

2

of

2

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
Hand		C. MONTOLIU et al., "Activation of the Metabotropic Glutamate Receptor mGluR5 Prevents Glutamate Toxicity in Primary Cultures of Cerebellar Neurons", The Journal of Pharmacology and Experimental Therapeutics, May 2, 1997; pp. 643-647; Vol. 281; The American Society of Pharmacology and Experimental Therapeutics; USA.	
X		Ksasovitskij et al., Chemical Abstracts, Vol. 123, No. 22, Abstract 299726w, 608h, page 477, 11/27/1995.	
X		Yurugi et al., Chemical Pharmaceutical Bulletin, Vol. 21, No. 8, pp., 1641-1650, 1973.	
X		William W. PAUDLER et al., "The Conversion of Imidazo[1,5-a]pyridines into 3-(2-Pyridyl)-1,2,4-oxadiazoles", Conversion of Imadazopyridines into Pyridyloxadiazoles", August 1967, pp. 2430-2433; Vol. 32; USA.	
X		T. Ross KELLY et al., "Total Synthesis of Dimethyl Sulfomycinamate", Tetrahedron Letters, 1995; pp. 5319-5322, Vol. 36, No. 30, Elsevier Science Ltd. UK.	
X		Wei HUANG et al., "A Novel Improved Procedure for the Synthesis of Oxazoles", Tetrahedron; 1996; pp. 10131-10136, Vol. 52, No. 30; Elsevier Science Ltd., UK.	
X		Mark A. MASSA et al., "Synthesis of Novel Substituted Pyridines as Inhibitors of Endothelin Converting Enzyme-1 (ECE-1); Bioorganic & Medicinal Chemistry Letters; 1998; pp. 2117-2122, Vol. 8, Elsevier Science Ltd., UK.	
X		Luciano VIO et al., "Note-low antihypertensive activity", Journal; 5807502; EN; 321; 1988; pgs. 713-717; Beilstein Instiut zur Foerderung der Chimischen Wissenschaften; Weinheim Germany.	
X		Helene PERRIER, et al., "Substituted Furans as Inhibitors of the PDE4 Enzyme"; Biorganic & Medicinal Chemistry Letters; 1999; pp. 323-326, Vol. 9, Elsevier Science Ltd. UK.	
		Edward E. GLOVER et al. "The Nitration of Imidazo[1,5-a] pyridines" J of the Chem. Soc., Perkins I, 1980, pp. 959-961.	
Hand		Robert K. HOWE et al., "Nitrile Oxide Cycloaddition Routes to 2-(Isoxazolyl)-benzoates and 2-(1,2,4-Oxadiazol-3-yl)benzoates", J. of Het. Chem., Vol. 19, 1982, pp. 721-726.	

X Did not receive

Examiner Signature	<i>Linn Davis</i>	Date Considered	4/8/2005
--------------------	-------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.